UNIGE document Scientific Article
previous document  unige:7096  next document
add to browser collection
Title

Combined therapy with saquinavir, ritonavir and stavudine in moderately to severely immunosuppressed HIV-infected protease inhibitor-naive patients
Authors
Battegay, M.
Vernazza, P. L.
Bernasconi, Enos
Flepp, Markus
Sendi, Pedram
Erb, P.
Malinverni, R.
Jaccard, Christophe
show hidden authors show all authors [1 - 11]
Published in HIV Medicine. 2001, vol. 2, no. 1, p. 35-42
Abstract OBJECTIVE: To assess the short-term and long-term effect of a combination of saquinavir, ritonavir and stavudine in moderately to severely immunosuppressed protease inhibitor-naive patients. DESIGN: Prospective open-label multicentre study. PATIENTS AND METHODS: A total of 64 protease inhibitor-naive and stavudine-naive HIV-infected patients with a CD4 count of < 250 cells/microL and > 10 000 HIV-1 RNA copies/mL received saquinavir hard-gelatin capsules, ritonavir and stavudine. Full (drop in viraemia of > 2 log10 and/or < 500 copies/mL) and partial responders (drop to between 500 and 5000 viraemia copies/mL) at week 9 (end of phase I) entered the second phase (additional 12-month period). RESULTS: Fifty-six patients completed phase I, 45 (70%) full responders and nine (14%) partial responders by intent-to-treat analysis. Thirty-nine patients completed phase II, 33 (52%) full responders and two (3%) partial responders. Six patients had < 50 HIV-1 RNA copies/mL at week 9, and 20 (31%) patients at month 12 of phase II. Mean CD4 cell counts increased significantly in the 56 patients from 89 to 184 cells/microL after 9 weeks and from 100 to 292 cells/microL in the 39 patients treated for another 12 months. Higher baseline viraemia and lower baseline CD4 cell counts were not associated with an unfavourable virological response at week 9 and month 12 of phase II. HIV DNA in peripheral blood monocytes decreased substantially (- 1.5 log10) but was detectable in all except one patient at the end of phase II. CONCLUSION: In protease- and stavudine-naive HIV-infected patients with moderate to severe immunosuppression, saquinavir in combination with ritonavir and stavudine caused a substantial long-term decrease in plasma viral load in approximately half the participants and a substantial increase in CD4 cell counts.
Keywords Adolescent — Adult — Aged — Cohort Studies — Drug Administration Schedule — Drug Therapy, Combination — Female — HIV Infections/ drug therapy — HIV Protease Inhibitors/administration & dosage/ therapeutic use — Humans — Immunocompromised Host — Male — Middle Aged — Prospective Studies — Reverse Transcriptase Inhibitors/administration & dosage/ therapeutic use — Ritonavir/administration & dosage/ therapeutic use — Saquinavir/administration & dosage/ therapeutic use — Stavudine/administration & dosage/ therapeutic use — Switzerland — Treatment Outcome — Viral Load
Identifiers
PMID: 11737374
Full text
Article - document accessible for UNIGE members only Limited access to UNIGE
Other version: http://www3.interscience.wiley.com/journal/118996607/abstract
Structures
Faculté de médecine / Section de médecine clinique / Département de médecine interne des spécialités
Citation
(ISO format) 		BATTEGAY, M. et al. Combined therapy with saquinavir, ritonavir and stavudine in moderately to severely immunosuppressed HIV-infected protease inhibitor-naive patients. In: HIV Medicine, 2001, vol. 2, n° 1, p. 35-42. https://archive-ouverte.unige.ch/unige:7096

204 hits

0 download

Contact an author

Update request

Update

Deposited on : 2010-06-21

Export document
Format :
Citation style :